Gastric amphicrine carcinoma with leptomeningeal metastases: A case report

Table 1 Whole course of the therapeutic regimens

Initiation of therapy to disease progression	Therapeutic stage	Therapeutic regimen	Medication usage	PFS (month)
April 17, 2025 to September 26, 2025	First-line therapy	SOX + tislelizumab	Oxaliplatin 120 mg, ivggt, d1; S1: 40 mg, po, bid, d1-14; tislelizumab 200 mg, ivggt, d1; a 21-day cycle	5
September 28, 2025 to November 27, 2025	Second-line therapy	FOLFIRI + tislelizumab	Irinotecan 200 mg, ivggt, d1; calcium folinate 300 mg, ivggt, d1; 5-fluorouracil 500 mg, bolus, d1; 5-fluorouracil 3000 mg, CIV, 46 hours; a 14-day cycle; tislelizumab 200 mg, ivggt, d1; a 21-day cycle	2
December 5, 2025 to January 22, 2026	Third-line therapy	Abraxane + zotuximab	Abraxane 200 mg, ivggt, d1; zotuximab 1000 mg as initial dose, 600 mg as maintenance dose, ivggt, d1; a 21-day cycle	1.6

CIV: Continuous intravenous infusion; ivggt: Intravenous guttae; PFS: Progression-free survival; S1: Tegafur gimeracil oteracil potassium capsule.

Table 2 Clinical characteristics and follow-up outcomes of patients with gastric amphicrine carcinoma

Ref.	Case	Sex	Age (year)	Lesion location	Size (cm)	TNM staging	Stage	Treatment	Outcomes (month)
Li et al[14], 2026	1	Male	52	Gastric body	4.5	T4aN2M0	IIIA	Surgery + chemotherapy	AWD, 15
	2	Male	69	Gastric antrum	4.3	T3N3aM0	IIIB	Surgery + chemotherapy	DOD, 6
	3	Male	53	Gastric antrum	4.0	T4aN3aM0	IIIB	Surgery + chemotherapy	NED, 18
	4	Male	72	Gastric cardia	4.0	T3N1M0	IIB	Surgery + chemotherapy	NED, 17
Chen et al[15], 2025	5	Male	64	Gastric cardia	4.0	T3N1M0	IIB	Surgery + chemotherapy	NED, 8
	6	Male	70	Gastric cardia	3.0	T3N2M0	IIIA	Surgery + chemotherapy	NED, 49
	7	Male	62	Gastric antrum	3.0	T3N3M0	IIIB	Surgery + chemotherapy	NED, 27
Qian and Feng[16], 2022	8	Male	69	Gastric body/antrum	8.5	TxN3bM0	IIIC	Surgery + chemotherapy	NED, 6
Sciarra et al[17], 2023	9	Male	63	Gastric cardia	1.2	T1b(sm)NxM0	IA	Surgery	NED, 18
Huang et al[18], 2019	10	Male	61	Gastric body	5.5	T4N1M0	IIIA	Surgery + chemotherapy	NED, 63
	11	Male	58	Gastric antrum	NA	T2N0M0	IB	Surgery	NED, 10
	12	Male	63	Gastric antrum	3.0	T1N0M0	IA	Surgery	NED, 10
	13	Male	56	Gastric body	2.5	T4N2M0	IIIA	Surgery	DOD, 42
	14	Male	68	Gastric antrum	4.5	T4N3bM0	IIIC	Surgery + chemotherapy	NED, 12
	15	Male	60	Gastric cardia	2.0	T4N1M0	IIIA	Surgery	DOD, 11
	16	Male	67	Gastric cardia	3.5	T3N0M0	IIA	Surgery + chemotherapy	NED, 6
Gao et al[19], 2025	17	Male	59	Gastric body	1.5	T1b (sm)N0M0	IA	ESD only	NED, 6
Current case	18	Male	66	Gastric antrum	3.0	T4N1M1	IV	Immunotherapy + chemotherapy	DOD, 10

Stage is according to the AJCC 8^th edition gastric cancer staging system. AWD: Alive with disease; DOD: Dead of disease; ESD: Endoscopic submucosal dissection; NED: No evidence of disease; TNM: Tumor-node-metastasis.